Mereo BioPharma Group PLC (LON:MPH) insider Denise Scots-Knight purchased 10,000 shares of the firm’s stock in a transaction on Thursday, July 18th. The stock was bought at an average price of GBX 51 ($0.67) per share, for a total transaction of £5,100 ($6,664.05).
Shares of MPH opened at GBX 41 ($0.54) on Monday. The firm has a market cap of $40.16 million and a price-to-earnings ratio of -0.91. The company has a fifty day moving average of GBX 56.28. Mereo BioPharma Group PLC has a fifty-two week low of GBX 40 ($0.52) and a fifty-two week high of GBX 320 ($4.18). The company has a debt-to-equity ratio of 65.56, a quick ratio of 2.05 and a current ratio of 2.13.
About Mereo BioPharma Group
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.